Guardian Investment Management Has $1.51 Million Stake in Pfizer Inc. (NYSE:PFE)

Guardian Investment Management lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 52,400 shares of the biopharmaceutical company’s stock after selling 7,005 shares during the period. Pfizer comprises approximately 1.2% of Guardian Investment Management’s investment portfolio, making the stock its 25th biggest holding. Guardian Investment Management’s holdings in Pfizer were worth $1,509,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer during the 4th quarter worth approximately $3,150,472,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $311,238,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 0.4 %

Pfizer stock traded down $0.09 during mid-day trading on Thursday, hitting $25.33. The company’s stock had a trading volume of 25,992,584 shares, compared to its average volume of 42,343,496. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market cap of $143.43 billion, a price-to-earnings ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The business has a 50 day moving average price of $27.19 and a 200-day moving average price of $28.76. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.